| Line Item | 2025-10-31 | Y/Y |
|---|---|---|
| R&D Expense | $94.5M | +146.6% |
| SG&A Expense | $28.7M | +19.6% |
| Operating Income | -$123.2M | -97.7% |
| Pre-tax Income | -$117.3M | -112.7% |
| Income Tax | $0 | +100.0% |
| Net Income | -$117.3M | -112.7% |
| EPS (Basic) | $2.29 | +56.8% |
| EPS (Diluted) | $2.29 | +56.8% |
| Line Item | 2025-10-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $50.2M | -71.0% |
| Short-term Investments | $143.6M | +119.8% |
| Current Assets | $201.4M | -18.6% |
| Total Assets | $221.5M | -28.8% |
| Current Liabilities | $32.0M | +118.1% |
| Total Liabilities | $53.8M | +39.4% |
| Stockholders' Equity | $167.7M | -38.5% |
| Line Item | 2025-10-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$99.2M | -105.5% |
| Capital Expenditures | $1.5M | +60.5% |
| Investing Cash Flow | -$25.1M | +80.0% |
| Financing Cash Flow | $1.5M | -99.4% |
| Free Cash Flow | -$100.7M | -104.7% |